Japan Tissue Engineering Co., Ltd. FY2027 Q1 Earnings Deep Dive Report

Japan's first regenerative medicine platform company, Japan Tissue Engineering Co., Ltd. (J-TEC, Securities Code: 7774) , achieved a landmark first quarter (1Q) for the fiscal year ending March 2027. Driven by the powerful impact of expanding the indications for its flagship autologous cultured cartilage product, 'JACC,' to include osteoarthritis (OA) , the company successfully transitioned from a year-ago loss to significant revenue growth and operating profitability .

This report provides a multi-faceted analysis of the 1Q financial results, the structural factors behind the profit and loss fluctuations, segment-specific progress, and the company's medium-to-long-term growth strategy.

---

1. 1Q Earnings Highlights: Significant Revenue Growth and Dramatic Turnaround to Profit

Performance in 1Q FY2027 showed substantial improvement across all profit levels compared to the same period last year.

• Net Sales : 766 million JPY (+340 million JPY / +80.3% YoY)
• Gross Profit : 512 million JPY (+296 million JPY / +137.2% YoY)
• Operating Profit/Loss : 59 million JPY profit (vs. 244 million JPY loss in the same period last year; +303 million JPY YoY)
• Ordinary Profit/Loss : 63 million JPY profit (vs. 241 million JPY loss in the same period last year; +304 million JPY YoY)
• Net Profit/Loss : 52 million JPY profit (vs. 242 million JPY loss in the same period last year; +294 million JPY YoY)

While SG&A expenses were leveled at 453 million JPY (down 2% YoY) under disciplined cost control, the primary driver of the significant return to profitability was the sharp increase in gross profit resulting from the rapid expansion of net sales. Regarding progress against the full-year plan, the company has already reached 59 million JPY (59.0% progress rate) against its full-year operating profit target of 100 million JPY, marking a strong start to the fiscal year.

---

2. Analysis of Operating Profit Fluctuations (Waterfall Structure)

An analysis of the +303 million JPY improvement in operating profit—from a 244 million JPY loss to a 59 million JPY profit—reveals that profit was generated through both favorable external conditions and self-help efforts.

The slide above is a waterfall chart detailing the factors behind the 1Q operating profit fluctuations. The following key drivers can be identified from this analysis:

1. External Environmental Factors (+94 million JPY) :
   • Increased sales of the autologous cultured epidermis 'JACE' due to a recovery in the number of severe burn patients (+140 million JPY).
   • Offset by a decline in revenue from the Teijin contract manufacturing business as the initial know-how transfer phase concluded (△46 million JPY).
2. Self-Help Factors (+209 million JPY) :
   • A surge in orders for the flagship product 'JACC' following the expansion of OA indications (+177 million JPY).
   • Growth in the melanocyte-containing autologous cultured epidermis 'JASMIN' through strengthened hospital-clinic collaboration and patient awareness initiatives (+12 million JPY).
   • Bottoming out and recovery in orders for NEPIC/OCULAR (+9 million JPY).
   • Progress in the development phases of clients in the Regenerative Medicine Contract Business (General Customer Contracts) (+41 million JPY).
   • Steady European expansion of the LaboSite business (+5 million JPY).
   • Other factors (increase in variable costs △50 million JPY, efficiency gains +15 million JPY, etc.; net △35 million JPY).

The fact that self-help efforts centered on 'JACC' (+209 million JPY) , rather than just external recovery in case numbers, served as the primary driver of profit growth underscores the high quality of this earnings recovery.

---

3. Detailed Trends by Segment and Product

(1) Regenerative Medicine Products Business: Net Sales 603 million JPY (+130.3% YoY)

The Regenerative Medicine Products business posted an operating profit of 240 million JPY (vs. 35 million JPY loss in the same period last year), driving the company-wide return to profitability.

• Skin Area (JACE, JASMIN) : Net Sales 316 million JPY (+94% YoY)
  • JACE : The number of severe burn cases, which had been sluggish in the previous fiscal year, showed a recovery trend, leading to very strong order performance.
  • JASMIN : 9 orders in 1Q alone, with a cumulative total of 26 cases including bookings for 2Q and beyond. The company has established hospital-clinic collaborations with 52 facilities nationwide, and patient awareness activities are yielding results.
• Cartilage Area (JACC) : Net Sales 255 million JPY (+226% YoY)
  • 111 cases acquired in 1Q alone (on track toward the annual target of 350 cases). The cumulative total, including orders for 2Q and beyond, has reached 220 cases. The number of contracted facilities has expanded to 143.
• Cornea Area (NEPIC, OCULAR) : Net Sales 30 million JPY (+47% YoY)
  • The downward trend at existing facilities has bottomed out, and the company is successfully acquiring orders from newly developed facilities.

(2) Regenerative Medicine Contract Business: Net Sales 94 million JPY (△5.0% YoY)

• General Customer Contracts : Net Sales 87 million JPY (+90% YoY)
  • High-value-added transitions to the 'clinical trial product manufacturing phase' for clients such as Actualize, VC Cell Therapy, Metcela, and AlliedCel are contributing steadily to revenue growth.
• Teijin Contract : Net Sales 7 million JPY (△85% YoY)
  • Revenue declined temporarily due to the completion of the know-how transfer phase, but milestone payments are expected to be recorded in the fourth quarter (4Q) , in line with the plan.

(3) LaboSite Business: Net Sales 68 million JPY (+8.0% YoY)

The LaboSite business, which sells 3D human cultured tissue models, performed steadily through follow-ups with 8 regular clients, new business development, and strengthened approaches to the medical device and materials markets.

---

4. The Overwhelming Market Potential and Growth Strategy for 'JACC'

'JACC' is the primary growth driver for the company's 5 billion JPY sales target .

The slide above illustrates the target market size and competitive advantages of 'JACC'.

Competitive Advantages and Market Potential of 'JACC'

1. The Only Approach Aiming for Structural Cure : Unlike conservative therapies such as exercise or medication, or artificial joint replacement, this is a curative treatment that regenerates cartilage by proliferating and transplanting the patient's own cartilage cells. Clinical trial results have confirmed a 97.4% repair rate .
2. Huge Potential Target Market :
   • Approximately 10 million people in Japan suffer from symptomatic osteoarthritis (OA).
   • The addressable candidate population, estimated from surgery numbers, is approximately 10,000 per year .
   • Even the initial target segment alone consists of approximately 1,000 people per year , representing a vast market opportunity.

Growth Strategy: Collaboration with OSB and Facility Development

As shown on the left side of the slide above, the company is promoting a business alliance with OSFerion Biomaterials (OSB) , the domestic market leader in artificial bone and bone void fillers, to accelerate the adoption rate of OA treatment.

• 'Cartilage Repair + Osteotomy' Combination : For OA patients, treatment combining 'osteotomy' (to correct misalignment; approx. 13,500 cases/year in Japan) and 'cartilage repair' is effective. In fact, approximately 60% of JACC cases are used in combination with osteotomy.
• Synergy Effects : By leveraging OSB's powerful sales network, the company is significantly strengthening its ability to develop facilities for JACC and its proposal capabilities, building an unshakable foundation for achieving 1,000 cases per year in the future.

---

5. Progress on New Pipelines and Global Expansion

Progress on pipelines and overseas expansion for medium-to-long-term corporate value enhancement is also steady.

1. Allogeneic Cultured Epidermis 'Allo-JaCE03' :
   • A new medical device product that uses cells from other donors as raw material, allowing for mass production and stockpiling. It is indicated for skin defects including burns, and procedures are proceeding smoothly toward approval application in FY2026 and approval within this fiscal year .
2. Autologous CAR-T Cell 'JPCAR019' :
   • An investigator-initiated Phase I/II clinical trial for acute lymphoblastic leukemia is underway. The company aims to complete the Phase I part within FY2027 and transition to the Phase II part.
3. European Expansion via German Subsidiary :
   • To strengthen local manufacturing and sales for the LaboSite business, the company established 'Japan Tissue Engineering Europe GmbH' in Heidelberg. The goal is to overcome the storage and transport risks of live cells and become the market leader in Europe, an advanced market for animal testing alternatives (scheduled to begin operations in the second half of FY2026).

---

6. Financial Soundness and Future Outlook

Financial health on the balance sheet (B/S) is another major strength of the company.

• Cash and Deposits : 3,347 million JPY (+96 million JPY vs. end of March 2026)
• Net Assets : 5,142 million JPY (+52 million JPY)
• Total Assets : 5,908 million JPY (+225 million JPY)
• Equity Ratio : 87.0% (extremely high level)

Maintaining a solid financial foundation with abundant self-funding—effectively a debt-free management style—the company possesses the financial strength to continue growth investments, such as R&D and overseas expansion, on its own.

Conclusion

The 1Q FY2027 earnings report marks a significant milestone, as the company transitioned from a year-ago loss to a clear profit-generating structure , primarily driven by a dramatic increase in orders due to the expansion of OA indications for 'JACC'.

Looking ahead, with multiple growth drivers in place—including further penetration of JACC through collaboration with OSB, strengthened hospital-clinic collaboration for JASMIN, the acquisition of approval for Allo-JaCE03 this fiscal year, and the launch of the European LaboSite subsidiary—the company is steadily executing its roadmap toward building a stable profit base and achieving exponential earnings growth.